 Pancreatic Neoplasms
"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.421 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Neoplasms, Pancreatic
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 3 | 0 | 3 | | 1982 | 0 | 2 | 2 | | 1983 | 6 | 0 | 6 | | 1984 | 3 | 0 | 3 | | 1985 | 2 | 0 | 2 | | 1986 | 4 | 0 | 4 | | 1987 | 1 | 4 | 5 | | 1988 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1990 | 3 | 0 | 3 | | 1991 | 1 | 0 | 1 | | 1992 | 6 | 1 | 7 | | 1993 | 4 | 0 | 4 | | 1994 | 9 | 4 | 13 | | 1995 | 5 | 2 | 7 | | 1996 | 2 | 0 | 2 | | 1997 | 2 | 1 | 3 | | 1998 | 2 | 1 | 3 | | 1999 | 5 | 1 | 6 | | 2000 | 2 | 1 | 3 | | 2001 | 6 | 0 | 6 | | 2002 | 7 | 8 | 15 | | 2003 | 3 | 1 | 4 | | 2004 | 6 | 2 | 8 | | 2005 | 22 | 3 | 25 | | 2006 | 14 | 3 | 17 | | 2007 | 18 | 3 | 21 | | 2008 | 19 | 3 | 22 | | 2009 | 18 | 3 | 21 | | 2010 | 19 | 2 | 21 | | 2011 | 20 | 4 | 24 | | 2012 | 9 | 2 | 11 | | 2013 | 21 | 3 | 24 | | 2014 | 23 | 1 | 24 | | 2015 | 16 | 2 | 18 | | 2016 | 27 | 2 | 29 | | 2017 | 20 | 5 | 25 | | 2018 | 18 | 2 | 20 | | 2019 | 29 | 3 | 32 | | 2020 | 14 | 2 | 16 | | 2021 | 5 | 1 | 6 | | 2022 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Gardiner A, Kidd J, Elias MC, Young K, Mabey B, Taherian N, Cummings S, Malafa M, Rosenthal E, Permuth JB. Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes. J Natl Cancer Inst. 2022 Jul 11; 114(7):996-1002.
-
Sela Y, Li J, Maheswaran S, Norgard R, Yuan S, Hubbi M, Doepner M, Xu JP, Ho ES, Mesaros C, Sheehan C, Croley G, Muir A, Blair IA, Shalem O, Dang CV, Stanger BZ. Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer. Cancer Res. 2022 05 16; 82(10):1890-1908.
-
Lakiza O, Lutze J, Vogle A, Williams J, Abukdheir A, Miller P, Liao C', Pitroda SP, Martinez C, Olivas A, Setia N, Kron SJ, Weichselbaum RR, Keutgen XM. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
-
Keutgen XM. First Differentiate and Then Operate (Or Not) : Editorial on "Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis". Ann Surg Oncol. 2022 06; 29(6):3371-3372.
-
Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest. 2022 02 15; 132(4).
-
Parilla M, Chapel D, Hechtman JF, Wanjari P, El Jabbour T, Sharma A, Ritterhouse L, Segal J, Vanderbilt C, Klimstra DS, Setia N, Tang L. Recurrent Loss of Heterozygosity in Pancreatic Neuroendocrine Tumors. Am J Surg Pathol. 2022 06 01; 46(6):823-831.
-
Sharma AE, Olivas A, Parilla M, Yassan L, Wang H, Zhang SS, Weber C, Keutgen XM, Hart J, Krausz T, Setia N. Epigenetic Dysregulation of 5-hydroxymethylcytosine in Well-Differentiated Pancreatic Neuroendocrine Tumors. Appl Immunohistochem Mol Morphol. 2022 02 01; 30(2):e11-e15.
-
Papageorge MV, de Geus SWL, Woods AP, Ng SC, McAneny D, Tseng JF, Kenzik KM, Sachs TE. The Effect of Hospital Versus Surgeon Volume on Short-Term Patient Outcomes After Pancreaticoduodenectomy: a SEER-Medicare Analysis. Ann Surg Oncol. 2022 Apr; 29(4):2444-2451.
-
Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer. 2022 02 01; 128(3):435-446.
-
Gonda TA, Farrell J, Wallace M, Khanna L, Janec E, Kwon R, Saunders M, Siddiqui UD, Brand R, Simeone DM. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium. Gastrointest Endosc. 2022 Apr; 95(4):723-732.e7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|